BioCardia’s CardiAMP Cell Therapy shows patient benefits in chronic myocardial ischemia trial
The CardiAMP Cell Therapy increased the exercise tolerance by 107-second and reduced angina episodes by 82% at the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 May 24
The CardiAMP Cell Therapy increased the exercise tolerance by 107-second and reduced angina episodes by 82% at the…
01 May 24
The positive top-line results revealed that the Phase 2/3 trial achieved its primary endpoint of improvement on the…
01 May 24
The partnership, spread across various therapeutic fields, aims to assess the use of polygenic risk scores in improving…
30 Apr 24
Enhertu demonstrated a statistically significant and clinically meaningful improvement in PFS against standard-of-care chemotherapy in the primary trial…
24 Apr 24
Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential…
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…
06 Mar 24
In the FLOW clinical trial, which enrolled 3,533 participants with type 2 diabetes and chronic kidney disease (CKD),…
01 Mar 24
Abrysvo bivalent RSV vaccine showed 77.8% efficacy against RSV-associated LRTD after disease surveillance in season two, and 88.9%…
29 Feb 24
Agreement spans wide range of Medidata’s solutions to enhance clinical trial efficiency
27 Feb 24
Gepotidacin is a triazaacenaphthylene antibiotic that acts as a bactericidal agent by hindering bacterial DNA replication through a…